Menu
Recruiting NCT06842407

Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

— Observational Healthy Donors

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Healthy Donors. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)

Overview

The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.

Primary outcome measures

  • Validation of molecular targets for immunotherapy [Time frame: 04.2023-06.2026]
  • Selection of therapeutic antibodies [Time frame: 04.2023-06.2026]
Secondary outcome measures (1)
  • Set up of immunological assays to adress monoclonal antibodies mechanism of action [Time frame: 04.2023-06.2026]

Eligibility criteria

Inclusion criteria

  • blood donors
  • age of 18 years or more
  • able to sign informed consent

Exclusion criteria

  • age below 18 years
  • Positive for HIV, HCV, HBV
  • not suitable for blood donation
  • not able to understand or sign informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Italy · 1 center
  • S.C. Medicina Trasfusionale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan

Identifiers

NCT: NCT06842407 · ID3411

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗